Blocking KV1.3 Channels Inhibits Th2 Lymphocyte Function and Treats a Rat Model of Asthma*

Background: CCR7− effector memory T lymphocytes are major players in lung inflammation that characterizes allergic asthma. Results: Blocking KV1.3 channels reduced the severity of an ovalbumin-induced model of asthma in rats. Conclusion: KV1.3 channels are attractive targets for immunomodulation and the treatment of allergic asthma. Significance: Selective KV1.3 channel blockers may prove beneficial in the treatment of asthma. Allergic asthma is a chronic inflammatory disease of the airways. Of the different lower airway-infiltrating immune cells that participate in asthma, T lymphocytes that produce Th2 cytokines play important roles in pathogenesis. These T cells are mainly fully differentiated CCR7− effector memory T (TEM) cells. Targeting TEM cells without affecting CCR7+ naïve and central memory (TCM) cells has the potential of treating TEM-mediated diseases, such as asthma, without inducing generalized immunosuppression. The voltage-gated KV1.3 potassium channel is a target for preferential inhibition of TEM cells. Here, we investigated the effects of ShK-186, a selective KV1.3 channel blocker, for the treatment of asthma. A significant proportion of T lymphocytes in the lower airways of subjects with asthma expressed high levels of KV1.3 channels. ShK-186 inhibited the allergen-induced activation of peripheral blood T cells from those subjects. Immunization of F344 rats against ovalbumin followed by intranasal challenges with ovalbumin induced airway hyper-reactivity, which was reduced by the administration of ShK-186. ShK-186 also reduced total immune infiltrates in the bronchoalveolar lavage and number of infiltrating lymphocytes, eosinophils, and neutrophils assessed by differential counts. Rats with the ovalbumin-induced model of asthma had elevated levels of the Th2 cytokines IL-4, IL-5, and IL-13 measured by ELISA in their bronchoalveolar lavage fluids. ShK-186 administration reduced levels of IL-4 and IL-5 and induced an increase in the production of IL-10. Finally, ShK-186 inhibited the proliferation of lung-infiltrating ovalbumin-specific T cells. Our results suggest that KV1.3 channels represent effective targets for the treatment of allergic asthma.

[1]  G. King.  Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics , 2015 .

[2]  H. Wulff,et al.  Blocking KCa3.1 Channels Increases Tumor Cell Killing by a Subpopulation of Human Natural Killer Lymphocytes , 2013, PloS one.

[3]  Bart N Lambrecht,et al.  Cytokine targets in airway inflammation. , 2013, Current opinion in pharmacology.

[4]  A. Lambertino,et al.  Epidemiology of asthma in the United States. , 2013, The Nursing clinics of North America.

[5]  B. Hoogendoorn,et al.  Differences in fungi present in induced sputum samples from asthma patients and non-atopic controls: a community based case control study , 2013, BMC Infectious Diseases.

[6]  R. Norton,et al.  Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. , 2012, Toxicon : official journal of the International Society on Toxinology.

[7]  I. Annesi-Maesano,et al.  Is the asthma epidemic still ascending? , 2012, Clinics in chest medicine.

[8]  P. Calabresi,et al.  Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis , 2012, The Journal of Immunology.

[9]  S. Feske,et al.  Ion channels , 2013, Thorax.

[10]  K. Chandy,et al.  Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.

[11]  I. Pavord,et al.  Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1 , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  K. Chandy,et al.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. , 2012, Toxicon : official journal of the International Society on Toxinology.

[13]  R. Norton,et al.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. , 2011, Inflammation & allergy drug targets.

[14]  D. Corry,et al.  Necessary and Sufficient Role for T Helper Cells To Prevent Fungal Dissemination in Allergic Lung Disease , 2011, Infection and Immunity.

[15]  S. Abramson,et al.  Respiratory tract allergic disease and atopy: experimental evidence for a fungal infectious etiology. , 2011, Medical mycology.

[16]  R. Bergman,et al.  The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. , 2011, The Journal of investigative dermatology.

[17]  B. Mazur,et al.  Cytokine Production by Peripheral Blood CD4+ and CD8+ T Cells in Atopic Childhood Asthma , 2010, Clinical & developmental immunology.

[18]  M. Rossi,et al.  Hydrogen sulfide improves neutrophil migration and survival in sepsis via K+ATP channel activation. , 2010, American journal of respiratory and critical care medicine.

[19]  P. Barnes.  New therapies for asthma: is there any progress? , 2010, Trends in pharmacological sciences.

[20]  D. Corry,et al.  A reversible, non-invasive method for airway resistance measurements and bronchoalveolar lavage fluid sampling in mice. , 2010, Journal of visualized experiments : JoVE.

[21]  K. Chandy,et al.  The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.

[22]  H. Wulff,et al.  The K+ channels KCa3.1 and Kv1.3 as novel targets for asthma therapy , 2009, British journal of pharmacology.

[23]  Brian J. Smith,et al.  Engineering a Stable and Selective Peptide Blocker of the Kv1.3 Channel in T Lymphocytes , 2009, Molecular Pharmacology.

[24]  M. Gollasch,et al.  BK channels in innate immune functions of neutrophils and macrophages. , 2009, Blood.

[25]  K. Chandy,et al.  Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. , 2008, Immunity.

[26]  B. Medoff,et al.  T cell trafficking in allergic asthma: the ins and outs. , 2008, Annual review of immunology.

[27]  Brian J. Smith,et al.  The D-Diastereomer of ShK Toxin Selectively Blocks Voltage-gated K+ Channels and Inhibits T Lymphocyte Proliferation* , 2008, Journal of Biological Chemistry.

[28]  A. Celada,et al.  Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages. , 2007, Biochemical and biophysical research communications.

[29]  S. Griffey,et al.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases , 2006, Proceedings of the National Academy of Sciences.

[30]  W. Nauseef,et al.  The Antibacterial Activity of Human Neutrophils and Eosinophils Requires Proton Channels but Not BK Channels , 2006, The Journal of general physiology.

[31]  P. Calabresi,et al.  The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Doi,et al.  Changes in histology and expression of cytokines and chemokines in the rat lung following exposure to ovalbumin. , 2005, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[33]  P. Calabresi,et al.  Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases , 2005, Molecular Pharmacology.

[34]  A. Braun,et al.  CD26 (dipeptidyl‐peptidase IV)‐dependent recruitment of T cells in a rat asthma model , 2005, Clinical and experimental immunology.

[35]  K. Chandy,et al.  K+ Channel Expression during B Cell Differentiation: Implications for Immunomodulation and Autoimmunity1 , 2004, The Journal of Immunology.

[36]  T. Out,et al.  Double Staining of Intracellular Cytokine Proteins and T-lymphocyte Subsets. Evaluation of the Method in Blood and Bronchoalveolar Lavage Fluid , 2004, The Histochemical Journal.

[37]  P. Calabresi,et al.  The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. , 2003, The Journal of clinical investigation.

[38]  K. Chandy,et al.  A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel Up-regulation in Chronically Activated T Lymphocytes* , 2003, The Journal of Biological Chemistry.

[39]  M. Petrović,et al.  Hypoxia Regulates Expression and Activity of Kv1.3 Channels in T Lymphocytes: A Possible Role in T Cell Proliferation1 , 2003, The Journal of Immunology.

[40]  K. Chandy,et al.  Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. , 2002, Biochemistry.

[41]  N. Jarjour,et al.  Pathogenesis of asthma. , 2002, The Medical clinics of North America.

[42]  R. Moqbel,et al.  Nitric oxide activates ATP‐dependent K+ channels in human eosinophils , 2002, Journal of leukocyte biology.

[43]  K. Chandy,et al.  Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Chung,et al.  Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. , 2001, Mediators of inflammation.

[45]  P. Giraud,et al.  Selective Blocking of Voltage-Gated K+ Channels Improves Experimental Autoimmune Encephalomyelitis and Inhibits T Cell Activation1 , 2001, The Journal of Immunology.

[46]  Mark J. Miller,et al.  Up-regulation of the IKCa1 Potassium Channel during T-cell Activation , 2000, The Journal of Biological Chemistry.

[47]  J Bousquet,et al.  Asthma. From bronchoconstriction to airways inflammation and remodeling. , 2000, American journal of respiratory and critical care medicine.

[48]  G. Pizzolo,et al.  Lymphocyte membrane antigen expression and intracellular cytokine patterns in an asymptomatic patient with persistently high serum levels of IgE. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[49]  J F Morrison,et al.  CCR7 (EBI1) receptor down-regulation in asthma: differential gene expression in human CD4+ T lymphocytes. , 1999, QJM : monthly journal of the Association of Physicians.

[50]  I. Levitan,et al.  Modulation of Olfactory Bulb Neuron Potassium Current by Tyrosine Phosphorylation , 1998, The Journal of Neuroscience.

[51]  C. Bunce,et al.  CD45RC Isoforms Define Two Types of CD4 Memory T Cells, One of which Depends on Persisting Antigen , 1997, The Journal of experimental medicine.

[52]  Todor A Popov,et al.  Spontaneous and induced sputum to measure indices of airway inflammation in asthma. , 1996, American journal of respiratory and critical care medicine.

[53]  G A Gutman,et al.  Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. , 1994, Molecular pharmacology.